WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H406105
CAS#: 194423-15-9
Description: PD-168393 is a potent, cell-permeable, irreversible, ATP-competitive and selective inhibitor of EGF receptor (EGFR) tyrosine kinase activity (IC50 = 700 pM).
Hodoodo Cat#: H406105
Name: PD-168393
CAS#: 194423-15-9
Chemical Formula: C17H13BrN4O
Exact Mass: 368.03
Molecular Weight: 369.222
Elemental Analysis: C, 55.30; H, 3.55; Br, 21.64; N, 15.17; O, 4.33
Synonym: PD168393; PD 168393; PD-168393.
IUPAC/Chemical Name: 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline
InChi Key: HTUBKQUPEREOGA-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H13BrN4O/c1-2-16(23)21-13-6-7-15-14(9-13)17(20-10-19-15)22-12-5-3-4-11(18)8-12/h2-10H,1H2,(H,21,23)(H,19,20,22)
SMILES Code: C=CC(NC1=CC2=C(NC3=CC=CC(Br)=C3)N=CN=C2C=C1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 369.22 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Skelton LA, Boron WF. Effect of acute acid-base disturbances on ErbB1/2 tyrosine phosphorylation in rabbit renal proximal tubules. Am J Physiol Renal Physiol. 2013 Dec 15;305(12):F1747-64. doi: 10.1152/ajprenal.00307.2013. Epub 2013 Oct 16. PubMed PMID: 24133121; PubMed Central PMCID: PMC3882443.
2: Poole NM, Nyindodo-Ogari L, Kramer C, Coons LB, Cole JA. Effects of tick saliva on the migratory and invasive activity of Saos-2 osteosarcoma and MDA-MB-231 breast cancer cells. Ticks Tick Borne Dis. 2013 Feb;4(1-2):120-7. doi: 10.1016/j.ttbdis.2012.09.003. Epub 2012 Nov 16. PubMed PMID: 23168047.
3: Turpaev K, Drapier JC. Stimulatory effect of benzylidenemalononitrile tyrphostins on expression of NO-dependent genes in U-937 monocytic cells. Eur J Pharmacol. 2009 Mar 15;606(1-3):1-8. doi: 10.1016/j.ejphar.2009.01.015. Epub 2009 Jan 21. PubMed PMID: 19374863.
4: Hammoud L, Burger DE, Lu X, Feng Q. Tissue inhibitor of metalloproteinase-3 inhibits neonatal mouse cardiomyocyte proliferation via EGFR/JNK/SP-1 signaling. Am J Physiol Cell Physiol. 2009 Apr;296(4):C735-45. doi: 10.1152/ajpcell.00246.2008. Epub 2009 Feb 11. PubMed PMID: 19211917.
5: Khalil MY, Grandis JR, Shin DM. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther. 2003 Jun;3(3):367-80. Review. PubMed PMID: 12820779.
6: Sun Y, Fry DW, Vincent P, Nelson JM, Elliott W, Leopold WR. Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res. 1999 Mar-Apr;19(2A):919-24. PubMed PMID: 10368634.
